Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives by Skoglund, Charlotte et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
This is an author produced version of a paper published in 
Biological psychiatry. This paper has been peer-reviewed 
but does not include the final publisher proof-corrections or 
journal pagination. 
 
Citation for the published paper: 
 
Biological psychiatry 2015; 77(10): 880-886 
 
Attention-deficit/hyperactivity disorder and risk for 
substance use disorders in relatives 
 
 
Skoglund, Charlotte; Chen, Qi; Franck, Johan; 
Lichtenstein, Paul; Larsson, Henrik 
 
 
URL: http://dx.doi.org/10.1016/j.biopsych.2014.10.006 
 
 
Access to the published version may require subscription. 
Published with permission from: Elsevier 
  
Words: 2878 
Abstract: 238 
Tables: 6 
References: 34 
Attention-Deficit Hyperactivity Disorder and Risk for Substance Use Disorders in 
Relatives 
 
Author list: Charlotte Skoglund1 M.D., Qi Chen2 M.D., Johan Franck1 PhD., Paul 
Lichtenstein2 PhD., Henrik Larsson2 PhD 
Author affiliations: 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, 
Sweden 
2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 
Sweden 
Corresponding author: Charlotte Skoglund, Karolinska Institutet, Department of Clinical 
Neuroscience, Administration Z5:00, SE-171 76 Stockholm, SWEDEN. Telephone: +46-8-
123 474 93. Telefax: +46-8-346563. E-mail: charlotte.skoglund@ki.se 
Key words: ADHD; Substance use disorder; Drug abuse; Alcohol use disorder; Comorbidity; 
Family study 
Conflict of interest disclosures: The authors state no conflicts of interest  
 
 	
  
 
 
Abstract 
Background: Previous research indicates that Attention-deficit hyperactivity disorder 
(ADHD) is highly associated with Substance Use Disorders (SUD). These studies however, 
have failed to clarify the nature of the overlap. The main aim was to explore if the overlap 
between ADHD and SUD could be explained by shared genetic and environmental factors or 
by harmful effects of ADHD medication.  
Method: Matched cohort design across different levels of family relatedness recorded from 
1973 to 2009. By linking longitudinal Swedish national registers, 62,015 ADHD probands 
and their first and second degree relatives were identified and matched 1:10 with non-ADHD 
controls and their corresponding relatives. Any record of SUD defined by discharge diagnoses 
of the International Classification of Diseases and/or a purchase of any drug used in the 
treatment of SUD. 
Result: First degree relatives of ADHD probands were at elevated risk for SUD (ORSUD1st 2.2 
and 1.8) compared to relatives of controls. The corresponding risk in second degree relatives 
was substantially lower (ORSUD2nd 1.4 and 1.4). The familial aggregation patterns remain 
similar for first degree and second degree relatives after excluding cases and controls with 
SUD as well as relatives with an ADHD diagnosis, and individuals with schizophrenia, 
bipolar disorder, depression and conduct disorder. 
Conclusion: Our findings suggest that the co-occurrence of ADHD and SUD are due to 
genetic factors shared between the two disorders, rather than to a general propensity for 
psychiatric disorders or harmful effects of ADHD medication.  
  
Introduction	
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly prevalent neuropsychiatric 
disorder characterized by impairing symptoms of hyperactivity, impulsivity and inattention 
(1). Individuals with ADHD are at increased risk for substance use disorders (SUD) (2) and 
they tend to have more serious SUD related problems and poorer treatment outcomes 
compared to individuals without ADHD (3). Previous studies however, have failed to clarify 
the nature of the overlap.  
A recent meta-analysis suggests that the association between ADHD and SUD 
varies across the different SUD-subtypes, possibly supporting a substance preference 
hypothesis in people with ADHD (2). The fact that some previous studies have used broad 
definitions of SUD (4-7), while others have explored the relationship between ADHD and 
specific SUD subtypes (such as psychoactive drug abuse, alcohol use disorder and nicotine 
dependence) (8-13) makes comparisons across studies difficult. Furthermore, since SUD, and 
particularly alcohol use disorder, is rare in childhood but increasing in prevalence with age 
through adolescence and into adulthood, short follow-up time is a serious limitation of many 
previous studies looking at the association between ADHD and SUD (4, 9). 
Previous family and twin studies have suggested a strong genetic predisposition 
for both ADHD (14) and SUD (5, 6, 10), but have produced inconsistent results regarding the 
nature of the overlap between the two disorders. Some genetically informed studies suggest 
shared genetic risk factors for ADHD and SUD (11, 15, 16), while other family-based studies 
indicate independent transmission of SUD and ADHD, or alternatively, the presence of an 
etiologically distinct ADHD plus SUD syndrome (7, 9, 12). Clearly, additional research is 
needed to resolve the conflicting results of previous research. 
Although many epidemiological studies seem to find no or possibly even 
protective, effects of ADHD medication on SUD (17, 18), there are still some lingering 
  
concerns about harmful effects of stimulant treatment stemming primarily from findings of 
animal and imaging studies (19-21). The fear that stimulant ADHD treatment may put 
susceptible individuals at risk for future SUD might, in fact, result in the withholding of 
effective pharmacological treatment in these individuals (22). A better understanding of the 
relationship between these two disorders might influence individuals with ADHD, their 
families, and clinicians to more readily accept ADHD pharmacotherapy in SUD patients. 
In this register-based family study, we aimed to further explore the extent to 
which genetic and environmental factors are shared between the two disorders. Importantly, 
by excluding individuals with ADHD from relatives to both cases and controls, we made 
attempts to rule out harmful effects of ADHD medication as a potential explanation to an 
observed familial association between ADHD and SUD. We also investigated whether ADHD 
is more strongly associated with any of the specific SUD subtypes, and the extent to which 
familial factors for ADHD and SUD were shared with other major psychiatric disorders 
previously shown to share genetic risk factors with ADHD (e.g. schizophrenia and bipolar 
disorder), and psychiatric disorders frequently coexisting with ADHD and SUD such as 
depression and conduct disorder. To this end, using nationwide register linkages, we 
identified 62,015 ADHD probands, their first and second degree relatives as well as 
approximately ten controls matched on birth year, sex, and residential information and their 
corresponding relatives.  
 
  
  
Method and Materials 
Data sources  
We utilized data from a record linkage of six population-based registries in 
Sweden; personal identification numbers enabled accurate linkage (23). The National Patient 
Register (NPR) provides data on psychiatric in-patient care since 1973 (ICD-8 to ICD-10) and 
out-patient care (ICD-10) since 2001 (24). The Swedish Prescribed Drug register (PDR) (25) 
contains information on drug identity (Anatomical Therapeutic Chemical [ATC-codes]) and 
dates of all registered prescriptions to the entire population in Sweden since July 2005. The 
Multi-Generation Register (MGR), contains information on the identity of the parents of all 
residents born in Sweden since 1932. The Cause of Death Register (CDR) provides 
information on dates of all registered deaths since 1958. The Migration Register (MR), 
includes information on dates of all registered migrations into or out of Sweden since 1969. 
The Total Population Register (TPR), includes information on sex, birth year, and migrant 
status for the entire Swedish population since 1969. The study was approved by the research 
ethics committee at The Karolinska Institute, Stockholm, Sweden Protocol Nr 2009/5:10. 
Measures 
We identified 47,794 patients with ADHD from the NPR (ICD-9: 314; ICD-10: 
F90) and 46,186 ADHD patients treated with stimulant or non-stimulant medication for 
ADHD (methylphenidate [N06BA04]; atomoxetine [N06BA09]; amphetamine [N06BA01]; 
dexamphetamine [N06BA02]) at any time between July 2005 and December 2009 from the 
PDR. Patients aged 3-65 years at the time of the first ADHD diagnosis (or first prescription of 
stimulant or non-stimulant medication for ADHD) were included. Among the 62,015 unique 
ADHD (42,118 males (68 %), 15,829 (25.5%) were identified from the NPR alone, 14,221 
(22.9 %) were identified from the PDR alone, and 31,965 (51.6 %) were identified from both 
the NPR and the PDR. 
  
We have previously validated the register-based ADHD diagnosis using data 
from 19,150 twins (born between 1992 and 2001) with psychiatric symptom information from 
the Swedish Twin Registry (26). ADHD symptoms were assessed using a well-validated 
measure of 96 specific child psychiatric symptoms (27). About 70% of the twins with a 
national register-based ADHD diagnosis recorded in the NPR or the PDR were also rated as 
screen-positive by parents. 
We acquired information on SUD using both ICD-codes from the NPR and 
ATC-codes in the PDR (using drugs exclusive in the treatment of SUD). Alcohol use disorder 
was defined using ICD-codes from the NPR (ICD-8: 291 and 303, ICD-9: 291, 303 and 305A 
and ICD-10: F10.0-F10.9). The alcohol use disorder index from the PDR was based on ATC-
codes for prescriptions of drugs used in the treatment of alcoholism (N07BB03 
(acamprosate), N07BB04 (natrexone) and N07BB01 (disulfiram)). Psychoactive drug abuse 
was measured by ICD-codes from the NPR (ICD-8: 304, ICD-9: 292, 304 and 305X and ICD-
10: F11.0-F16.9) and ATC-codes from the PDR (N02AE01 (buprenorfine), N07BC51 
(buprenorfine+naltrexone) and N07BC02 (methadone)). 
For each case, we randomly selected ten unaffected control subjects. By 
matching life time non-ADHD control subjects on birth year, sex and residential factors we 
ensured equal follow-up time. According to well-established procedures for nested case-
control designs (23, 28), controls were alive and living in Sweden and had not been diagnosed 
with ADHD at the time of the first ADHD diagnosis of the proband. 
Statistical Analyses  
The statistical analyses were performed using a nested case-control design. To 
explore the familial overlap between ADHD and SUD, we compared relatives of ADHD 
probands with relatives of controls matched on birth year, sex and residential information. 
This method allows equal follow-up periods of the relatives to the probands and controls and 
  
minimizes bias introduced when individuals in the population registries enter the study at 
different time points (i.e., left truncation) (28). We compared the risk separately for first and 
second degree relatives based on the following assumptions; a) first degree relatives share 
approximately 50% of their co-segregating genes and are thereby more genetically similar 
than second degree relatives who only share approximately 25% of their co-segregating genes 
and b) maternal half-siblings are more similar with regard to shared environmental exposures 
than paternal half-siblings since children continue to live predominantly with their mothers 
following parental separation (28). 
We controlled for the possibility that the familial association was due to ADHD 
medication by excluding ADHD in relatives of both cases and controls from the analyses. We 
also simultaneously excluded family pairs with SUD in cases and controls to minimize the 
possibility that, the co-occurrence of the two disorders could reflect an etiologically distinct 
“ADHD plus SUD” sub syndrome. 
 We also explored whether the observed familial aggregation pattern remained 
similar after excluding all individuals with a diagnosis of schizophrenia (ICD-8: 295.0-295.4, 
295.6, 295.8-295.9; ICD-9: 295A-295E, 295G, 295W, 295X; ICD-10: F20) or bipolar 
disorder (ICD-8: 296.1, 296.3, 296.8; ICD-9: 296A/C/D/E/W; ICD-10: F30-F31) in the NPR. 
This was done to explore the extent to which the familial factors for ADHD and SUD were 
shared with other major psychiatric disorders that have previously been found to share genetic 
risk factors with ADHD (29, 30). Furthermore, to explore if the association was driven by 
other psychiatric disorders frequently coexisting with ADHD and SUD (3, 31, 32), we 
excluded all individuals with a diagnosis of depression (ICD8: 296.2, 298.0, 300.4; ICD9: 
296B, 300E; ICD10: F32-F34 and conduct disorder (ICD9: 312; ICD-10: F91) in the NPR. 
We performed two different sensitivity analyses to test the robustness of our results. First, we 
explored if the familial association was driven by the fact that 40,300 families contributed 
  
with more than one case-relative pair, by selecting and analyzing a sample with only one 
case-relative pair per family. Secondly, we explored the validity of the ADHD diagnosis by 
analyzing a sample of individuals identified as ADHD cases in both the NPR and the PDR.  
To describe associations, we used odds ratios (ORs) with 95% confidence 
intervals (95% CIs) obtained from conditional logistic regression models in PROC PHREG in 
SAS version 9.3. When studying associations within the same families (e.g. not statistically 
independent of one another), CIs were obtained with a robust sandwich estimator function to 
adjust for non-independence (PROC PHREG, covsandwich option). 
 
 
  
  
Results 
Table 1 shows distribution for study variables among ADHD probands, 
matched controls and their corresponding relatives and odds ratios for ADHD associated with 
each comorbid disorder. Probands with ADHD were more likely to have been diagnosed with 
SUD, drug abuse and alcohol use disorder compared to age, sex and residency matched 
controls (ORSUD 10.8 95 % CI; 10.5-11.1, ORDrug 19.2, 95% CI; 18.5-19.8, ORAlc 8.3, 95% CI; 
8.0-8.5). 
Table 2 shows the numbers and percentages of SUD for first and second degree 
relatives to ADHD probands versus controls. First degree relatives of ADHD probands were 
at elevated risk for SUD (ORSUD1st 2.2 and 1.8) compared to relatives of controls. The 
corresponding risk in second degree relatives was substantially lower and similar for maternal 
and paternal half-siblings (ORSUD2nd 1.4 and 1.4).  
Table 3 shows that the risk for SUD still was higher in first degree compared to 
second degree relatives of ADHD probands even after excluding disorders that share genetic 
risk factors with ADHD such as bipolar disorder or schizophrenia (ORSUD1st 2.2 and 1.7; 
ORSUD2nd 1.4 and 1.4). Table 4 shows that the increased risk for SUD remains after exclusion 
of coexisting disorders such as depression (ORSUD1st 2.2 and 1.7; ORSUD2nd 1.4 and 1.3). Table 
5 and 6 shows the results of the two different sensitivity analyses. As can be seen, the results 
were robust not only when a sample with one case-relative pair per family was used (ORSUD1st 
2.2 and 1.8; ORSUD2nd 1.3 and 1.2), but also in a sample with ADHD cases identified in the 
NPR and the PDR (ORSUD1st 2.4 and 1.9; ORSUD2nd 1.5 and 1.4). 
 
  
  
Discussion 
This population-based case-cohort study found a strong familial association 
between ADHD and SUD. Our results show that the risk for SUD increases considerably with 
increased genetic relatedness to an ADHD proband. The familial aggregation patterns 
remained similar after excluding cases and controls with SUD as well as relatives with an 
ADHD diagnosis and thereby support the hypothesis that the association between ADHD and 
SUD is explained by shared familial risk factors rather than the harmful effects of ADHD 
medication. Furthermore, since our results show similar risks between maternal and paternal 
half-siblings, the familial effect most probably reflects genetic factors rather than shared 
environmental factors. The understanding of the shared and specific genetic and 
environmental risk factors underlying co-occurring psychiatric disorders is still limited. Based 
on the findings of this study, we predict that future molecular genetic studies will identify 
genetic risk variants that are shared across ADHD and SUD, perhaps reflecting variants 
involved in dopaminergic mesolimbic reward pathways, or neural systems involved in 
impulse control (20). This, in turn, may generate a better understanding of the 
pathophysiological mechanisms that are common to ADHD and SUD. 
Our finding has potentially important implications for clinical practice and 
future research. The main clinical implication is that the overlap between ADHD and SUD is 
likely not explained by harmful effects of stimulant medication. This is important, given that 
concerns around the safety of central stimulant treatment in ADHD might result in the 
withholding of essential and effective pharmacological treatment in affected individuals. The 
main research implication is the clarification of inconclusive results from previous family 
studies of ADHD and SUD (5, 7, 9, 10, 12, 15). That is, some of the previous family studies 
have found that only relatives of ADHD probands with co-occurring SUD had an increased 
risk of SUD, but not relatives to probands with ADHD alone. This has been interpreted as 
  
support for ADHD plus SUD being a distinct sub-syndrome influenced by a specific pattern 
of genetic and environmental risk factors. In contrast to these previous findings, we found that 
pure ADHD in probands actually predicted pure SUD in relatives, which supports the 
hypothesis of shared familial risk factors for the co-occurrence of the two disorders. A 
potential explanation for the conflicting results is that previous studies might have been 
underpowered to detect a true familial association between ADHD and SUD. 
Since previous studies (29, 30) have shown pleiotropic effects of genetic risk 
variants across a broad range of diagnostic categories, including schizophrenia, bipolar 
disorder and ADHD, we also explored the extent to which the genetic factors for ADHD and 
SUD were shared with bipolar disorder and schizophrenia. We found that the familial 
aggregation pattern remained similar after excluding individuals with a diagnosis of bipolar 
disorder and schizophrenia suggesting that at least part of the genetic overlap is specific for 
ADHD and SUD. Also, both ADHD and SUD are known to frequently co-occur with 
depression (3, 31) and conduct disorder (32). However, our results were robust after 
excluding these conditions suggesting that the association are not primarily driven by co-
existing depression or conduct disorders.  
In this study we also addressed the issue of short follow-up time, which has 
been a serious limitation of some of the previous family-based studies (4, 9). SUD is unusual 
in children but gets more frequent with increasing age. Insufficient follow up time is a 
possible explanation to previous inconsistent results. By providing a maximal follow-up time 
of 36 years (1973-2009) the possibility of capturing SUD cases increases dramatically.  
 Our results should also be interpreted in the context of some limitations. ADHD 
probands and their relatives might be more exposed to healthcare interventions resulting in an 
obvious risk of detection bias. Given the significant time trend in the diagnosis of ADHD (33) 
the observed association for parents could be overestimated due to under-diagnosis of ADHD 
  
in older people. This might explain why the risk is higher for parents compared to siblings. 
Also, the ascertainment of ADHD cases was predominantly based on ICD-10 diagnosis of 
hyperkinetic disorder and prescribed medication unique for the treatment of ADHD. The 
ICD-10 definition of ADHD is stricter compared with that in DSM-IV, and the national 
guidelines for medication of ADHD, issued by the Swedish National Board of health and 
Welfare in 2002, state that medication should be reserved for cases where other supportive 
interventions have failed, indicating that our proxies for ADHD most likely underestimates 
the incidence of ADHD and identifies severe ADHD cases. Thus, our strategies probably 
could not avoid producing false negatives, while we consider bias due to false positives more 
unlikely. By excluding individuals with ADHD from relatives to both cases and controls we 
draw the conclusion that familial factors rather than harmful effects of stimulant medication 
drive the association between ADHD and SUD. This conclusion relies on the assumption that 
central stimulant medication is used almost uniquely in the treatment of ADHD and that 
individuals without a diagnosis of ADHD are therefore not exposed to ADHD medication. 
This study contributes to the growing body of genetically informed research 
concerning the nature of the observed overlap between ADHD and SUD by specifically 
addressing the hypothesis of shared genetic risk factors for ADHD and SUD. An improved 
understanding of the etiologic underpinnings of SUD and ADHD is crucial and will have 
important clinical and public health implications. Familial history of ADHD needs to be taken 
into account when assessing risk for future SUD since it is not only the individual themself, 
but also their relatives who are at risk for SUD, should an ADHD diagnosis be established.  
With further understanding of the etiological overlap between the two disorders, 
clinicians might be able to target individuals at high risk for SUD at an early stage, thus 
preventing the development of a more severe addiction disorder. Also, further exploration of 
genetic underpinnings of both disorders is important to individualize and optimize future 
  
psychosocial and pharmacological treatment. Theoretically, individuals with a genetic 
susceptibility for ADHD and SUD might benefit from different treatment options than 
individuals without such hereditary risk factors (34). 
Finally, individuals with ADHD and SUD not only experience great personal 
suffering and functional impairment but are also exposed to a variety of misunderstandings, 
misinterpretations and misclassification regarding their ADHD symptoms and SUD disorders. 
Not only could a clearer understanding of the etiological overlap between ADHD and SUD 
increase societal acceptance for them as valid medical diagnoses, but it could also reduce the 
personal and psychosocial stigmatization associated with both disorders and ensure that these 
individuals receive effective treatment. 
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Table 1 Distribution of study variables among ADHD probands and matched controls, and 
odds ratios for ADHD associated with each comorbid disorder 
 
 No. (%)	  
 ADHD  
(n=62,015)	
Controls  
(n=619,794)	
Odds ratio  
(95% CI)	
Sex	    
  Male	 42,118 (67.9)	 420,824 (67.9)	  
  Female	 19,897 (32.1)	 198,970 (32.1)	  
Relatives	    
  Parents (Females, %)	 85,399(50.2)	 760,358 (50.2)	  
  Full siblings (Females, %)	 51,005 (50.7)	 478,353 (50.9)	  
  Maternal half siblings (Females, %)	 20,992 (50.3)	 160,458 (50.7)	  
  Paternal half siblings (Females, %)	 23,099 (50.0)	 179,316 (50.1)	  
Outcomes	    
  Substance use disorder	 12,021 (19.4)	 15,471 (2.5)	 10.8(10.5-11.1) 	
  Drug abuse	 8349 (13.5)	 5606 (0.9)	 19.2 (18.5 –	19.8)	
  Alcohol use disorder	 7574 (12.2)	 11,132 (1.8)	 8.3 (8.0 - 8.5)	
Comorbid disorders	    
  Bipolar disorder	 3199 (5.2)	 1771 (0.3)	 20.1 (19.0 - 21.1)	
  Schizophrenia	 639 (1.0)	 947 (0.2)	 6.9 (6.4 - 7.6)	
  
  Depression	 12,032 (19.4)	 13,489 (2.2)	 12.8 (12.5 - 13.1)	
  Conduct disorder	 2990 (4.8)	 1034 (0.2)	 31.4 (29.5 - 33.6)	
 
 
  
Table 2 Risk for substance use disorder, drug abuse and alcohol use disorder in relatives to 
ADHD probands compared to relatives to controlsa  
 Substance use disorders in 
relatives	
Drug abuse in relatives	 Alcohol use disorders in 
relatives	
 ADHD 
N (%)	
Control 
N (%)	
OR 
(95 % 
CI)	
ADHD 
N (%)	
Control 
N (%)	
OR 
(95 % 
CI)	
ADHD 
N (%)	
Control 
N (%)	
OR 
(95 % 
CI)	
1°	relatives	          
Parent	 7555(8.9)	 31,748(4.2)	
2.2 
(2.2 - 
2.3)	
3514 
(3.8)	
12,921 
(1.6)	
2.4 
(2.4-
2.5)	
6024 
(6.5)	
24,868 
(3.0)	
2.3 
(2.2-
2.3)	
Full sibling	 1805(3.5)	 9564(2.0)	
1.8 
(1.7 - 
1.9)	
870 
(1.6)	
3563 
(0.7)	
2.4 
(2.2-
2.5)	
1553 
(2.8)	
8137 
(1.5)	
1.8 
(1.7-
1.9)	
2°	relatives	          
Maternal 
half-sibling	 1098(5.2)	 6291(3.9)	
1.4 
(1.3 - 
1.5)	
585 
(2.6)	
3003 
(1.7)	
1.6 
(1.5-
1.8)	
849 
(3.6)	
5080 
(2.8)	
1.4 
(1.3-
1.5)	
Paternal 
half-sibling	 1170(5.1)	 7068(3.9)	
1.4 
(1.3 - 
1.4)	
602 
(2.4)	
3474 
(1.7)	
1.5 
(1.4-
1.6)	
914 
(3.5)	
5467 
(2.6)	
1.4 
(1.3-
1.5)	
 
 
 
a after exclusion of probands and controls with SUD and relatives to probands or controls with ADHD and after exclusion of probands and 
controls with SUD, relatives to probands or controls with ADHD. 
 
  
  
Table 3 Risk for SUD, in relatives to ADHD probands compared to relatives to controls, after 
exclusion of individuals with bipolar disorder and schizophrenia	
 Substance use disorder in relatives	
ADHD  
N (%)	
Control 
N (%)	
OR 
(95 % CI)	
1°	relatives	
Parent	 6805 (8.4)	 28,109 (4.0)	 2.2 (2.2-2.3)	
Full sibling	 1562 (3.2)	 8409 (1.9)	 1.7 (1.7-1.8)	
2°	relatives 	
Maternal half-sibling	 1017 (5.1)	 5657 (3.7)	 1.4 (1.3-1.5)	
Paternal half-sibling	 1050(4.8)	 6228 (3.7)	 1.4 (1.3-1.4)	
 
 
 
SUD= Substance use disorder; ADHD=attention deficit-hyperactivity disorder; OR=Odds Ratio; CI=Confidence Interval
  
Table 4 Risk for SUD, in relatives to ADHD probands compared to relatives to controls, after 
exclusion of individuals with depression and conduct disorder 
 Substance use disorder in relatives	
ADHD  
N (%)	
Control 
N (%)	
OR 
(95 % CI)	
1°	relatives	
Parent	 4450 (7.0)	 17,113 (3.2)	 2.2 (2.2-2.3)	
Full sibling	 1007 (2.5)	 5369 (1.5)	 1.7 (1.6-1.8)	
2°	relatives 	
Maternal half-sibling	 664 (4.1)	 3455 (3.0)	 1.4 (1.3-1.5)	
Paternal half-sibling	 687 (3.9)	 3905 (3.1)	 1.3 (1.2-1.4)	
 
 
 
SUD= Substance use disorder; ADHD=attention deficit-hyperactivity disorder; OR=Odds Ratio; CI=Confidence Interval 
 	
  
Table 5 Risk for SUD in relatives to ADHD probands compared to relatives to controls using 
a sample with one case-relative pair per familya 
 
 Substance use disorder in relatives 
ADHD  
N (%) 
Control 
N (%) 
OR 
(95 % CI) 
1°  relatives 
Parent 
4002 (9.0) 16,679 (4.2) 2.2 (2.2-2.3) 
Full sibling 
1044 (3.3) 5611 (1.9) 1.8 (1.7-1.9) 
2°  relatives 
Maternal half-sibling 607 (4.8) 3737 (3.9) 1.3 (1.2-1.4) 
Paternal half-sibling 566 (4.5) 3758 (3.8) 1.2 (1.1-1.3) 
 
 SUD= Substance use disorder; ADHD=attention deficit-hyperactivity disorder; OR=Odds Ratio; CI=Confidence Interval 
a40300 families > one case-parent pair ,12940 families > one case-sibling pair,5578 families > one case-maternal sibling pair, 6502 families 
> one case-paternal sibling pair. 
  
  
Table 6 Risk for SUD in relatives to ADHD probands compared to relatives to controls using 
a sample with ADHD cases identified from the NPR and the PDR 
 
 Substance use disorder in relatives 
ADHD  
N (%) 
Control 
N (%) 
OR 
(95 % CI) 
1°  relatives 
Parent 
4211 (9.6) 17,686 (4.2) 2.4 (2.3-2.5) 
Full sibling 
935 (3.7) 4849 (2.0) 1.9 (1.8-2.0) 
2°  relatives 
Maternal half-sibling 659 (5.5) 4020 (3.8) 1.5 (1.4-1.7) 
Paternal half-sibling 669 (5.2) 4403 (3.9) 1.4 (1.3-1.5) 
 
 SUD= Substance use disorder; ADHD=attention deficit-hyperactivity disorder; OR=Odds Ratio; CI=Confidence Interval 
 
 
